US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Healthcare stocks have been under the weather for the past few years, underperforming the broader market’s rally despite ...

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.

Alzheimer's disease Therapeutics Market. LAS VEGAS, NV, UNITED STATES, January 23, 2025 /EINPresswire / -- DelveInsight's“Acute Respiratory Distress Synd ...

A new study suggests clinical utility of the first FDA-approved genetic test to help gauge an individual’s risk for opioid ...